[Department Circular No. 2021- 0331] The Health Technology Assessment Council (HTAC) releases its updated evidence summaries for COVID-19 Vaccine Assessments

MEMORANDUM- REQUEST FOR COMMENTS ON EVALUATION FRAMEWORK FOR COVID-19 VACCINES (VERSION 2)

[DEPARTMENT CIRCULAR NO. 2021- 0348] Coresia Vaccine Certificate Survey for Key Stakeholders

Preliminary recommendation on Tenofovir/Lamivudine/Dolutegravir (TLD)

[Department Memorandum No. 2021- 0317] Non-inclusion of Pazopanib as a Second-line Treatment for Metastatic Soft Tissue (mSTS) Sarcoma in the Philippine National Formulary (PNF)

[Department Circular No. 2021- 0273] HTAC Issuance on Acceptance and processing of Health Technologies under Monitored Release with Phase IV Trial Data

Preliminary recommendation on two-dose Inactivated Polio Vaccine (IPV)

[Department Memorandum No. 2021- 0294] Non-inclusion of Lapatinib in the Philippine National Formulary

[Department Memorandum No. 2021- 0264] Health Technology Assessment Council’s (HTAC) Recommendation on COVID-19 Vaccine Moderna

[Department Memorandum No. 2021- 0252] Health Technology Assessment Council’s (HTAC) Recommendations on RT-PCR and Rapid Antigen Testing for COVID-19

Preliminary Recommendation on Lapatinib

[Department Memorandum No. 2021- 0242] inclusion of Nicotine replacement therapy (NRT) and Varenicline in the Primary Care Formulary

[Department Memorandum No. 2021- 0227] Health Technology Assessment Council’s (HTAC) Recommendations on COVID-19 heath technologies